Meningococcal group B vaccines

J. Findlow
DOI: https://doi.org/10.4161/hv.24689
2013-06-06
Human Vaccines & Immunotherapeutics
Abstract:Meningococcal disease caused by the encapsulated organism Neisseria meningitidis remains a feared and devastating illness due to its rapid onset and associated morbidity and mortality. Differences in the polysaccharide capsule surrounding the organism allow classification into 12 groups, of which A, B, C, W and Y are predominantly responsible for invasive disease. The introduction of monovalent group C glycoconjugate vaccines (MCC) into the UK schedule in 1999 has successfully achieved group C (MenC) disease control,1 resulting in group B (MenB) now being responsible for >80% of invasive disease. This disease burden disproportionately effects children <5 years with peak incidence in infants <1 year of age with a second smaller peak in adolescents.2
What problem does this paper attempt to address?